In recent developments, Anavex Life Sciences has reported encouraging results from a long-term study evaluating its investigational
therapy, Anavex 2-73, for Parkinson’s disease dementia. The extension study of
the Phase 2 ANAVEX 2-73-PDD-001 trial demonstrated that one year of treatment
with Anavex 2-73 effectively reduced symptom severity in 20 patients.
The initial Phase 2 trial, which involved 132 adults, revealed that administration of Anavex 2-73
led to improvements in memory and cognitive skills, as well as significant
reductions in both motor and non-motor symptoms. The positive outcomes prompted
researchers to extend the study to further assess long-term efficacy and safety.
Participants in the extension study took Anavex 2-73 daily for 48 weeks. During a gap period caused by the COVID-19
pandemic, when patients were not on the medication, symptoms worsened. However,
upon resuming Anavex 2-73 treatment, participants showed notable improvements.
Median scores on the Movement Disorder Society-Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS) returned to levels comparable to those at the end of the original Phase 2 trial.
Christopher Missling, PhD, president and CEO of Anavex, emphasized the significance of these findings. He noted that the data
suggests Anavex 2-73 has the potential to address the urgent unmet need for
effective treatments in Parkinson’s disease.
Anavex 2-73 is designed to activate the SIGMAR1 receptor, which plays a crucial role in
maintaining brain cell health. Given the receptor’s reduced levels in
Parkinson’s, Alzheimer’s, and Rett syndrome patients, Anavex Life Sciences is investigating
the drug’s potential across multiple neurological conditions.
The company plans to launch a pivotal Phase 3 trial to further evaluate the therapy’s efficacy.
If successful, this data will support regulatory applications for Anavex 2-73.
This investigational therapy continues to show promise, bringing hope to many affected
by neurodegenerative diseases. Refer to this article for related information.
Find more information about Anavex on https://www.linkedin.com/company/anavex-life-sciences
ibbya329ut4ih024t
Share post:
In recent developments, Anavex Life Sciences has reported encouraging results from a long-term study evaluating its investigational
therapy, Anavex 2-73, for Parkinson’s disease dementia. The extension study of
the Phase 2 ANAVEX 2-73-PDD-001 trial demonstrated that one year of treatment
with Anavex 2-73 effectively reduced symptom severity in 20 patients.
The initial Phase 2 trial, which involved 132 adults, revealed that administration of Anavex 2-73
led to improvements in memory and cognitive skills, as well as significant
reductions in both motor and non-motor symptoms. The positive outcomes prompted
researchers to extend the study to further assess long-term efficacy and safety.
Participants in the extension study took Anavex 2-73 daily for 48 weeks. During a gap period caused by the COVID-19
pandemic, when patients were not on the medication, symptoms worsened. However,
upon resuming Anavex 2-73 treatment, participants showed notable improvements.
Median scores on the Movement Disorder Society-Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS) returned to levels comparable to those at the end of the original Phase 2 trial.
Christopher Missling, PhD, president and CEO of Anavex, emphasized the significance of these findings. He noted that the data
suggests Anavex 2-73 has the potential to address the urgent unmet need for
effective treatments in Parkinson’s disease.
Anavex 2-73 is designed to activate the SIGMAR1 receptor, which plays a crucial role in
maintaining brain cell health. Given the receptor’s reduced levels in
Parkinson’s, Alzheimer’s, and Rett syndrome patients, Anavex Life Sciences is investigating
the drug’s potential across multiple neurological conditions.
The company plans to launch a pivotal Phase 3 trial to further evaluate the therapy’s efficacy.
If successful, this data will support regulatory applications for Anavex 2-73.
This investigational therapy continues to show promise, bringing hope to many affected
by neurodegenerative diseases. Refer to this article for related information.
Find more information about Anavex on https://www.linkedin.com/company/anavex-life-sciences